Genmab — Februar 2019

[E_L]

don't think it was posted yet?

[E_L]

• Alcyone: After receiving 9 cycles of D-VMP, then just on Dara alone for maintenance; infection risk in the first 9 cycles; after that not many side effects; great strategy in this group of elderly patients
  (-> Dara only is cheaper as well offcourse)

[E_L]

• MAIA: for the elderly it is practice changing, SC future hightly convenient. Will be on-label very soon. “February 1st it will be standard therapy for me…”

[Bulder]

In think it is recorded before ash. But nevertheless they were all excited about dara. Fonseca: Maia curves much better than SWOG. I think he is exaggerating. Better but not much better.

[Bulder]

Important though in an elderly frail population: DRd seems milder than RVd.

[JørgenVarnæs]

er der nogen, der har tallene på tisotumab respons i cervical og bladder? Jeg tænker på N for population og patienter med respons

[JørgenVarnæs]

jeg kan ikke lige se de tal fra The Lancet - men kun responsraten for de 2 indikationer

[E_L]

does escalation 2 bladder, 2 cervical (from 27)

[E_L]

dose expansion 15 bladder 34 cervical (from 147)

[E_L]

table 1 from the link at 09:57

[JørgenVarnæs]

I've tried opening your link a few times since you posted. I cannot connect

[nohope]

Prøv lige igen, link virker her.

[JørgenVarnæs]

so we are looking at 4 responses in bladder and 9 responses in cervical?

[JørgenVarnæs]

har prøvet 5 gange nu

[bibob]

Også ok her.

[nohope]

ok

[JørgenVarnæs]

hverken i edge eller chrome

[nohope]

https://sci-hub.tw/10.1016/s1470-2045(18)30859-3

[JørgenVarnæs]

nope - still nothing

[nohope]

Ok, ingen ideer så.